Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00308906 · ClinicalTrials.gov registry record
Identification of Gene and Protein Markers of Kidney Injury in Aminoglycoside-treated Children
A clinical trial of Infection and Renal Dysfunction, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- 166
- Enrollment target
- 2
- Study locations
NCT00308906: Completed study of Infection and Renal Dysfunction, sponsored by Virginia Commonwealth University.
NCT00308906 is a study of Infection and Renal Dysfunction that has completed, run by Virginia Commonwealth University. The registered enrollment target is 166 participants, below the 722-participant average among 41 other Infection trials with a reported enrollment target (77% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00308906, a study of Infection and Renal Dysfunction, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- 166 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purposes of this study are to identify potential gene and protein markers of aminoglycoside-induced kidney injury in infants, children and adolescents treated with aminoglycoside antibiotics.
Conditions Studied
Interventions
- DRUG aminoglycoside
Study Locations (2)
Kentucky
- University of Lousiville - Louisville
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2006-06 |
| Est. Completion | 2010-12 |
What the finished NCT00308906 record still lists
NCT00308906 is an observational study that tracks outcomes without assigning an intervention. The registered 166 participants enrollment target is mid-sized for trials with a published cap, below the 722-participant average among 41 other Infection trials with a reported enrollment target (77% lower).
The record links to 2 conditions, with Infection appearing as the primary indexed condition, and to 1 intervention - of which aminoglycoside is the first listed.
NCT00308906 reports a single indexed study location in Kentucky, Virginia.
Frequently Asked Questions
What is clinical trial NCT00308906 about?
NCT00308906 is a clinical study titled "Identification of Gene and Protein Markers of Kidney Injury in Aminoglycoside-treated Children". The purposes of this study are to identify potential gene and protein markers of aminoglycoside-induced kidney injury in infants, children and adolescents treated with aminoglycoside antibiotics.
What is the current status of trial NCT00308906?
This trial is currently completed. The enrollment target is 166 participants. The study started on 2006-06. Estimated completion is 2010-12.
What conditions does trial NCT00308906 study?
This clinical trial studies the following conditions: Infection, Renal Dysfunction.
What interventions are being tested in trial NCT00308906?
The interventions under investigation include: aminoglycoside (DRUG).
Who is sponsoring clinical trial NCT00308906?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00308906 being conducted?
This trial has 2 study locations across Kentucky, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00308906's enrollment target sits among peer trials
166 22nd of 41 higher than 20 of 41 other Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Home Hospital for Suddenly Ill Adults
RECRUITING · NA
-
Copper Supplementation in Cirrhosis
RECRUITING · NA
-
Persona Revision Knee System Outcomes
RECRUITING
-
NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
RECRUITING · Phase 1
-
Diagnosis and Management of Inflammatory and Infectious Diseases
RECRUITING
-
BLOOM: Pragmatic Feasibility Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747303 · 166 participants · Phase 2
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
- NCT03806283 · 166 participants
Mechanisms of Pregnancy Vascular Adaptations
- NCT04040452 · 166 participants · Phase 4
Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery
- NCT04375813 · 166 participants · Phase 2
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia